We have screened for the presence of codon-132 mutations in the IDH1 gene in a large cohort of 1305 gliomas, including 436 WHO grade II, 394 WHO grade III, and 475 WHO grade IV gliomas. This evidence concerns the gene IDH1 and central nervous system cancer.